Trial
NCT00244218
Response to Phenylketonuria to Tetrahydrobiopterin (BH4)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
The University of Texas Medical Branch, Galveston
Collaborators
—
Condition
Phenylketonuria
Intervention
tetrahydrobiopterin (BH4)
Why stopped
The FDA has approved Kuvan (BH4) as a therapeutic agent for phenylketonuria
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-09-21